Principles of Immunotherapy

  • Jennifer L. Joscelyn
  • Lloyd Kasper
Part of the Current Clinical Neurology book series (CCNEU)


Immunotherapeutic intervention varies from immunomodulation, which adjusts the immune system back toward a state of homeostasis, to immunosuppression, which ablates specific compartments or pathways involved in the pathologic process. These approaches carry both benefit and risk. This chapter will discuss current and future principles of immunotherapeutic approaches.


Autoimmunity Lymphocytes NK cells Chemokines Receptors Blood–brain barrier 


  1. 1.
    Kasper L. Haque, Azizul., Haque, Sakhina DA Regulatory mechanisms of the immune system in multiple sclerosis. T regulatory cells: turned on to turn off. J Neurol. 2007;254 Suppl 1:110–4.Google Scholar
  2. 2.
    Duddy M et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092–9.PubMedGoogle Scholar
  3. 3.
    Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci. 2003;998:457–72.PubMedGoogle Scholar
  4. 4.
    Blanco P et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19(1):41–52.PubMedGoogle Scholar
  5. 5.
    Dittel BN. CD4 T cells: balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain Behav Immun. 2008;22(4):421–30.PubMedGoogle Scholar
  6. 6.
    Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008;28(6):697–706.PubMedGoogle Scholar
  7. 7.
    Kasper G et al. Matrix metalloprotease activity is an essential link between ­mechanical stimulus and mesenchymal stem cell behavior. Stem Cells. 2007;25(8):1985–94.PubMedGoogle Scholar
  8. 8.
    Chang X et al. Foxp3 controls autoreactive T cell activation through transcriptional regulation of early growth response genes and E3 ubiquitin ligase genes, independently of thymic selection. Clin Immunol. 2006;121(3):274–85.PubMedGoogle Scholar
  9. 9.
    Chang X et al. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med. 2005;202(8):1141–51.PubMedGoogle Scholar
  10. 10.
    Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101(5):455–8.PubMedGoogle Scholar
  11. 11.
    Taylor A et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology. 2006;117(4):433–42.PubMedGoogle Scholar
  12. 12.
    Miyara M, Sakaguchi SD-M. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13(3):108–16.PubMedGoogle Scholar
  13. 13.
    Reder AT et al. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol. 1984;16(2):242–9.PubMedGoogle Scholar
  14. 14.
    Sakaguchi S, Wing K, Miyara MD-N. Regulatory T cells – a brief history and perspective. Eur J Immunol. 2007;37 Suppl 1:S116–23.PubMedGoogle Scholar
  15. 15.
    Abbas AK, Lichtman A. Cellular and molecular immunology. 2nd ed. Philadelphia: Saunders Elsevier; 2006. p. 324.Google Scholar
  16. 16.
    Zhang C, Zhang J, et al. The regulatory effect of natural killer cells: do “NK-reg cells” exist? Cell Mol Immunol. 2006;3(4):241–54.PubMedGoogle Scholar
  17. 17.
    Li Z, Lim WK, et al. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol. 2005;174(9):5187–91.PubMedGoogle Scholar
  18. 18.
    Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19–49.PubMedGoogle Scholar
  19. 19.
    Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol. 2007;26(1–2):95–119.PubMedGoogle Scholar
  20. 20.
    Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297–336.PubMedGoogle Scholar
  21. 21.
    Yamaura A et al. Human invariant Valpha24+ natural killer T cells acquire regulatory functions by interacting with IL-10-treated dendritic cells. Blood. 2008;111(8):4254–63.PubMedGoogle Scholar
  22. 22.
    Godfrey DI, McCluskey J, Rossjohn J. CD1d antigen presentation: treats for NKT cells. Nat Immunol. 2005;6(8):754–6.PubMedGoogle Scholar
  23. 23.
    Burrows PD, Cooper MD. B-cell development in man. Curr Opin Immunol. 1993;5(2):201–6.PubMedGoogle Scholar
  24. 24.
    Tangye SG et al. BAFF, APRIL and human B cell disorders. Semin Immunol. 2006;18(5):305–17.PubMedGoogle Scholar
  25. 25.
    Uckun FM. Regulation of human B-cell ontogeny. Blood. 1990;76(10):1908–23.PubMedGoogle Scholar
  26. 26.
    Sun J, Lin Z, et al. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol. 2008;597(1–3):1–5.PubMedGoogle Scholar
  27. 27.
    Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557–67.PubMedGoogle Scholar
  28. 28.
    Schneider P et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–56.PubMedGoogle Scholar
  29. 29.
    Gross JA et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995–9.PubMedGoogle Scholar
  30. 30.
    Thompson JS et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293(5537):2108–11.PubMedGoogle Scholar
  31. 31.
    Krumbholz M et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195–200.PubMedGoogle Scholar
  32. 32.
    Nardelli B et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97(1):198–204.PubMedGoogle Scholar
  33. 33.
    Ng LG et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173(2):807–17.PubMedGoogle Scholar
  34. 34.
    Craxton A et al. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood. 2003;101(11):4464–71.PubMedGoogle Scholar
  35. 35.
    Katsenelson N et al. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol. 2007;37(7):1785–95.PubMedGoogle Scholar
  36. 36.
    Meyer-Bahlburg A, Rawlings DG. B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev. 2008;7(4):313–6.PubMedGoogle Scholar
  37. 37.
    Cheema GS et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313–9.PubMedGoogle Scholar
  38. 38.
    Groom J et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109(1):59–68.PubMedGoogle Scholar
  39. 39.
    Krumbholz M et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008;131(Pt 6):1455–63.PubMedGoogle Scholar
  40. 40.
    Hamzaoui K et al. Serum BAFF levels and skin mRNA expression in patients with Behcet’s disease. Clin Exp Rheumatol. 2008;26(4 Suppl 50):S64–71.PubMedGoogle Scholar
  41. 41.
    Thangarajh M et al. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol. 2004;152(1–2):183–90.PubMedGoogle Scholar
  42. 42.
    Thien M et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785–98.PubMedGoogle Scholar
  43. 43.
    Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz). 2008;56(2):77–83.Google Scholar
  44. 44.
    Hawker K. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol. 2008;21 Suppl 1:S19–25.PubMedGoogle Scholar
  45. 45.
    Chan OT et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189(10):1639–48.PubMedGoogle Scholar
  46. 46.
    Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol. 1990;8:773–93.PubMedGoogle Scholar
  47. 47.
    Lund FE et al. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun. 2005;8:25–54.PubMedGoogle Scholar
  48. 48.
    Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today. 1997;18(7):343–50.PubMedGoogle Scholar
  49. 49.
    Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol. 2004;172(6):3422–7.PubMedGoogle Scholar
  50. 50.
    Banchereau J et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881–922.PubMedGoogle Scholar
  51. 51.
    Fillatreau S et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944–50.PubMedGoogle Scholar
  52. 52.
    Mizoguchi A et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002;16(2):219–30.PubMedGoogle Scholar
  53. 53.
    Mauri C et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003;197(4):489–501.PubMedGoogle Scholar
  54. 54.
    Matsushita T et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118(10):3420–30.PubMedGoogle Scholar
  55. 55.
    Serafini B et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164–74.PubMedGoogle Scholar
  56. 56.
    Sims GP et al. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol. 2001;167(4):1935–44.PubMedGoogle Scholar
  57. 57.
    Roxanis I et al. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol. 2002;125(1–2):185–97.PubMedGoogle Scholar
  58. 58.
    Aloisi F et al. Lymphoid chemokines in chronic neuroinflammation. J Neuroimmunol. 2008;198(1–2):106–12.PubMedGoogle Scholar
  59. 59.
    Magliozzi R et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089–104.PubMedGoogle Scholar
  60. 60.
    Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26(9):485–95.PubMedGoogle Scholar
  61. 61.
    Man S, Ubogu EE, Ransohoff RM. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 2007;17(2):243–50.PubMedGoogle Scholar
  62. 62.
    Allt G, Lawrenson JG. Is the pial microvessel a good model for blood-brain barrier studies? Brain Res Brain Res Rev. 1997;24(1):67–76.PubMedGoogle Scholar
  63. 63.
    Kivisakk P et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA. 2003;100(14):8389–94.PubMedGoogle Scholar
  64. 64.
    Provencio JJ et al. Comparison of ventricular and lumbar cerebrospinal fluid T cells in non-inflammatory neurological disorder (NIND) patients. J Neuroimmunol. 2005;163(1–2):179–84.PubMedGoogle Scholar
  65. 65.
    Weller RO et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009;117(1):1–14.PubMedGoogle Scholar
  66. 66.
    Konat GW, Borysiewicz E, Fil D, James I. Peripheral challenge with double- stranded RNA elicits global up-regulation of cytokine gene expression in the brain. J Neurosci Res. 2009;87(6):1381–8.PubMedGoogle Scholar
  67. 67.
    Schenkel AR, Mamdouh Z. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat Immunol. 2004;5(4):393–400.PubMedGoogle Scholar
  68. 68.
    Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610–21.PubMedGoogle Scholar
  69. 69.
    Cardona AE et al. Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J Leukoc Biol. 2008;84(3):587–94.PubMedGoogle Scholar
  70. 70.
    Bazan JF et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–4.PubMedGoogle Scholar
  71. 71.
    Avolio C et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler. 2005;11(4):441–6.PubMedGoogle Scholar
  72. 72.
    Takabe K et al. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181–95.PubMedGoogle Scholar
  73. 73.
    Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397–407.PubMedGoogle Scholar
  74. 74.
    Cuvillier O et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381(6585):800–3.PubMedGoogle Scholar
  75. 75.
    Graler MH et al. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem. 2003;89(3):507–19.PubMedGoogle Scholar
  76. 76.
    Wang W, Huang MC, Goetzl EJ. Type 1 sphingosine 1-phosphate G protein-coupled receptor (S1P1) mediation of enhanced IL-4 generation by CD4 T cells from S1P1 transgenic mice. J Immunol. 2007;178(8):4885–90.PubMedGoogle Scholar
  77. 77.
    Terai K et al. Edg-8 receptors are preferentially expressed in oligodendrocyte ­lineage cells of the rat CNS. Neuroscience. 2003;116(4):1053–62.PubMedGoogle Scholar
  78. 78.
    Allende ML et al. S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB J. 2008;22(1):307–15.PubMedGoogle Scholar
  79. 79.
    Shiow LR et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006;440(7083):540–4.PubMedGoogle Scholar
  80. 80.
    Lande R et al. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol. 2008;67(5):388–401.PubMedGoogle Scholar
  81. 81.
    Wakkach A et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18(5):605–17.PubMedGoogle Scholar
  82. 82.
    Ito T et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007;204(1):105–15.PubMedGoogle Scholar
  83. 83.
    Meriggioli MN et al. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci. 2008;1132:276–82.PubMedGoogle Scholar
  84. 84.
    Itano AA et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity. 2003;19(1):47–57.PubMedGoogle Scholar
  85. 85.
    Tarbell KV, Yamazaki S. The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity. Semin Immunol. 2006;18(2):93–102.PubMedGoogle Scholar
  86. 86.
    Groux H, Fournier N. Role of dendritic cells in the generation of regulatory T cells. Semin Immunol. 2004;16(2):99–106.PubMedGoogle Scholar
  87. 87.
    Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006;110(1):35–56.PubMedGoogle Scholar
  88. 88.
    Zhao W et al. Stat2-dependent regulation of MHC class II expression. J Immunol. 2007;179(1):463–71.PubMedGoogle Scholar
  89. 89.
    Alison MR, Islam S. Attributes of adult stem cells. J Pathol. 2009;217(2):144–60.PubMedGoogle Scholar
  90. 90.
    Conover JC, Notti RQ. The neural stem cell niche. Cell Tissue Res. 2008;331(1):211–24.PubMedGoogle Scholar
  91. 91.
    Rice CM, Scolding NJ. Adult stem cells-reprogramming neurological repair? Lancet. 2004;364(9429):193–9.PubMedGoogle Scholar
  92. 92.
    Singec I, Snyder EY. Inflammation as a matchmaker: revisiting cell fusion. Nat Cell Biol. 2008;10(5):503–5.PubMedGoogle Scholar
  93. 93.
    Whone AL, Scolding NJ. Mesenchymal stem cells and neurodegenerative disease. Clin Pharmacol Ther. 2009;85(1):19–20.PubMedGoogle Scholar
  94. 94.
    Korbling M, Estrov Z, Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant. 2003;32 Suppl 1:S23–4.PubMedGoogle Scholar
  95. 95.
    Burt RK et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8(3):244–53.PubMedGoogle Scholar
  96. 96.
    Burt RK et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102(7):2373–8.PubMedGoogle Scholar
  97. 97.
    Burt RK et al. The promise of hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2003;31(7):521–4.PubMedGoogle Scholar
  98. 98.
    Freedman MS, Atkins HL. Suppressing immunity in advancing MS: too much too late, or too late for much? Neurology. 2004;62(2):168–9.PubMedGoogle Scholar
  99. 99.
    Li Y et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology. 2002;59(4):514–23.PubMedGoogle Scholar
  100. 100.
    Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.PubMedGoogle Scholar
  101. 101.
    Zappia E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755–61.PubMedGoogle Scholar
  102. 102.
    Larghero J, Vija L, Lecourt S, Michel L, Verrecchia F, Farge D. Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases? Rev Med Interne. 2009;30(3):287–99.PubMedGoogle Scholar
  103. 103.
    Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009;57(11):1192–203.PubMedGoogle Scholar
  104. 104.
    Wang M et al. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 2009;126(2):220–32.PubMedGoogle Scholar
  105. 105.
    Yadirgi G, Marino S. Adult neural stem cells and their role in brain pathology. J Pathol. 2009;217(2):242–53.PubMedGoogle Scholar
  106. 106.
    Pluchino S et al. Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain. 2008;131(Pt 10):2564–78.PubMedGoogle Scholar
  107. 107.
    Ben-Hur T et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003;41(1):73–80.PubMedGoogle Scholar
  108. 108.
    Pluchino S, Martino G. The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J Neurol Sci. 2008;265(1–2):105–10.PubMedGoogle Scholar
  109. 109.
    Patrikios P et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129(Pt 12):3165–72.PubMedGoogle Scholar
  110. 110.
    Patani R et al. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol. 2007;33(3):277–87.PubMedGoogle Scholar
  111. 111.
    Franklin RJ, Kotter MR. The biology of CNS remyelination: the key to therapeutic advances. J Neurol. 2008;255 Suppl 1:19–25.PubMedGoogle Scholar
  112. 112.
    Kuhlmann T et al. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain. 2008;131(Pt 7):1749–58.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jennifer L. Joscelyn
    • 1
  • Lloyd Kasper
    • 2
  1. 1.HooksettUSA
  2. 2.Dartmouth Medical SchoolLebanonUSA

Personalised recommendations